Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL

Clinical trial NCT04052659 · UNKNOWN

Trial details

NCT number: NCT04052659
Sponsor: Peking University
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Peripheral T-cell Lymphoma

Start date: 2021-04-15
Primary completion: 2024-12-30
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.